Abbisko Cayman (2256) reported that Abbisko Therapeutics, its subsidiary, has successfully dosed the first patient in a Phase I/II clinical study of ABSK141, an oral, highly potent, and selective small-molecule KRAS G12D inhibitor. This open-label trial targets patients with advanced solid tumors harboring KRAS G12D mutations, including pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer.

According to Abbisko Cayman (2256), the study received Investigational New Drug approvals from the U.S. Food and Drug Administration and the China National Medical Products Administration in December 2025. KRAS G12D is a common oncogenic driver gene found in various solid tumors, and no targeted therapy for this mutation has been approved globally.

Abbisko Cayman (2256) emphasized that there is no guarantee ABSK141 will achieve successful marketing in the future. Founded in April 2016, Abbisko Therapeutics focuses on discovering and developing innovative oncology treatments, with ABSK141 representing its latest milestone in advancing KRAS-targeted therapies.